Image Source: Pexels

The portfolio of stocks I started building on September 8, at a one stock per week pace for the next year, is named Vista. I will select its fourteenth stock this weekend. Vista is the sixth portfolio I've built (at a one dividend dog per-week pace) since 2014. Six portfolios = VI for Vista!

Vista is planned to Look Ahead for Outstanding, Proven, Dividend Winners. (Like Aristocrats)

Today I'll review the fifth of five healthcare sector stock candidates vying to be that fourteenth selection in  Vista.

My subject today is a large-cap drug manufacturer - a general company named GlaxoSmithKline PLC. Its trading ticker symbol is GSK. This is my second report on GlaxoSmithKline Plc for Vista and it was selected as the 52nd pick in my Volio portfolio (The fifth one).

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. 

The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. 

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

I use three key data points to gauge dividend equities or funds like GlaxoSmithKline PLC:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether a company has made, is making, and will make money. 

GSK Price

GSK's price per share closed at $37.98 yesterday. A year ago its price was $46.29. Price is down $8.31 or nearly 18% on the year.

If GSK's stock trades in the range of $30 to $50 this next year, its recent $37.98 price might rise by $7.02. to reach $45.00 by December 11, 2021. 

GSK Dividends

GSK's most recently declared quarterly dividend was $0.4959 payable on January 14th. Dividends are estimated to total $1.97 per share annually and yield 5.19% at yesterday's $37.98 closing price.

GSK Gains?

Adding the $1.97 annual anticipated dividend to my $7.02 optimistic estimate of GlaxoSmithKline PLC's price upside shows an $8.99 potential gross gain, per share, to be reduced by any costs to trade the shares.  

Put little under $1,000.00 today in GlaxoSmithKline PLC at $37.98 and we would buy 26 shares GSK stock.

A $10 broker fee (if any) paid half at purchase and half at sale could cost us about $0.38 per share.

Subtract that maybe $0.38 brokerage cost from my estimated  $8.99 gross gain per share results in a net gain of $8.61 X 26 shares = $223.86 or a 22.4% net gain on a $987.48 investment.

So it goes that GlaxoSmithKline PLC shows a possible 22.4% net gain including a 5.19% dividend yield. It could be more, it could be less. 

All of the estimates above are speculation based on the past history of GlaxoSmithKline PLC. Only time and money invested in this stock will determine its worth.